C4 Therapeutics Q4 EPS $(0.18) Beats $(0.31) Estimate, Sales $11.016M Beat $6.460M Estimate
Benzinga Newsdesk 8 months ago
EarningsEarnings BeatsNews
C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.31) by 41.37 percent. This is a 63.27 percent increase over losses of $(0.49) per share from
C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.31) by 41.37 percent. This is a 63.27 percent increase over losses of $(0.49) per share from the same period last year. The company reported quarterly sales of $11.016 million which beat the analyst consensus estimate of $6.460 million by 70.53 percent. This is a 112.79 percent increase over sales of $5.177 million the same period last year.